Linezolid-induced pure red cell aplasia in a patient with staphylococcus epidermidis infection after allogeneic stem cell transplantation

Transplant Infectious Disease

Volumn 14, Issue 4, 2012, Pages

  Waki, F ^a   Ohnishi, H ^a   Shintani, T ^a   Uemura, M ^a   Matsumoto, K ^a   Fukumoto, T ^a   Kitanaka, A ^a   Kubota, Y ^a   Tanaka, T ^a   Ishida, T ^a   Matsunaga, T ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Linezolid; Pure red cell aplasia; Staphylococcus epidermidis; Stem cell transplantation

Indexed keywords

ACICLOVIR; ACLARUBICIN; AMPHOTERICIN B LIPID COMPLEX; CILASTATIN PLUS IMIPENEM; CYTARABINE; FAMOTIDINE; FLUCONAZOLE; FLUDARABINE; HEMOGLOBIN; LEUKOCYTE ANTIGEN; LINEZOLID; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; URSODEOXYCHOLIC ACID; VANCOMYCIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANISOCYTOSIS; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; BONE MARROW EXAMINATION; CASE REPORT; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE APLASIA; ERYTHROID CELL; GRAFT VERSUS HOST REACTION; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY INJURY; LEUKOCYTE; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NEUTROPHIL; ORAL MUCOSAL DISEASE; POIKILOCYTOSIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REMISSION; RETICULOCYTE COUNT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-INFECTIVE AGENTS; BACTEREMIA; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; RED-CELL APLASIA, PURE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84865175840     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00728.x     Document Type: Article

References (26)

1. Cohen N, Mihu CN, Seo SK, et al. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1337-1341.
2. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 (Suppl S2): ii45-53.
3. Kuter DJ, Phil D, Tillotson GS, et al. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21 (8): 1010-1013.
4. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46 (8): 2723-2726.
5. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001; 285 (10): 1291.
6. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin J Dis 2002; 35 (3): e29-31.
7. Taketani T, Kanai R, Fukuda S, et al. Pure red cell precursor toxicity by linezolid in a pediatric case. J Pediatr Hematol Oncol 2009; 31 (9): 684-686.
8. Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990; 75 (1): 290-295.
9. Malfuson JV, Amor RB, Bonin P, et al. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation. Vox Sang 2007; 92 (1): 85-89.
10. Greigoor PS, Weimar W. Tacrolimus and pure red-cell aplasia. Am J Transplant 2005; 5 (1): 195-196.
11. Suzuki S, Yoshio O, Ichiro N, et al. Pure red cell aplasia induced by FK506. Transplantation 1996; 61 (5): 831-832.
12. Misra S, Moore TB, Ament ME, Busuttil RW, Macdiarmid SV. Red cell aplasia in children on tacrolimus after liver transplantation. Transplant 1998; 65 (4): 575-577.
13. Kako S, Kand Y, Oshima K, et al. Late onset autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol 2008; 83 (3): 247-249.
14. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-Induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-520.
15. Diekema DJ, Jones RN. Oxazolidinones: a review. Drugs 2000; 59 (1): 7-19.
16. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-3255.
17. Dessypris EN, Lipton JM. Red cell aplasia. In: Greer JP, Foerster J, Rodgers GM, et al., eds. Wintrobe's Clinical Hematology. (12th edn.) Philadelphia: Lippincott Williams & Wilkins, 2009: 1421-1437.
18. Dessypris EN, Redline S, Harris JW, Lrantz SB. Diphenylhydantoin-induced pure red cell aplasia. Blood 1985; 65 (4): 789-794.
19. Zyvoxam. Zyvoxam (linezolid) Package Insert, Kalamazoo, Michigan: Pharmacia and Upjohn, 2000.
20. Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54 (4): 798-802.
21. Whitehouse T, Capeda JA, Chulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55 (3): 333-340.
22. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrobial Agents Chemother 2003; 47 (9): 2775-2780.
23. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32 (12): 2437-2442.
24. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42 (13): 1129-1140.
25. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42 (1): 66-72.
26. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54 (4): 832-835.